NCT02756845: Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors

NCT02756845
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 2 Years to 21 Years (Child, Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients over the age of 21; Patients with clinically active brain metastases; Prior treatment with a tumor vaccine, talimogene laherparepvec, or any other oncolytic virus
https://ClinicalTrials.gov/show/NCT02756845

Comments are closed.

Up ↑